Windtree Therapeutics, Inc. announced that it has entered into a Common Stock Purchase Agreement with an equity line investor whereby the Company has the right, but not the obligation, to sell to the Purchaser, and the Purchaser is obligated to purchase newly issued shares of the Company?s common stock, par value $0.001 per share for the gross proceeds of up to $35,000,000 on June 26, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.19 USD | +2.57% | -0.93% | -75.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-75.35% | 1.89M | |
+16.59% | 44.44B | |
-10.62% | 37.68B | |
+41.16% | 39.84B | |
+29.92% | 31.46B | |
-9.78% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- WINT Stock
- News Windtree Therapeutics, Inc.
- Windtree Therapeutics, Inc. announced that it expects to receive $35 million in funding